Detalles de la búsqueda
1.
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Blood
; 124(9): 1426-33, 2014 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25006120
2.
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
Cancer
; 120(7): 976-82, 2014 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24339028
3.
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.
Clin Pharmacol Ther
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38752712
4.
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Br J Haematol
; 163(2): 214-22, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24033250
5.
Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.
Eur J Clin Pharmacol
; 69(3): 327-39, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22782539
6.
Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors.
Clin Ther
; 42(11): 2214-2224, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33139055
7.
Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
Drug Metab Dispos
; 36(8): 1519-28, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18458048
8.
Strategic and Statistical Considerations on the QT Assessment of Volasertib.
Ther Innov Regul Sci
; 52(4): 416-422, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29714574
9.
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.
Clin Pharmacokinet
; 57(3): 379-392, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28631179
10.
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Lung Cancer
; 104: 126-130, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28212994
11.
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Clin Lung Cancer
; 14(1): 19-27, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22658814
12.
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study.
Leuk Lymphoma
; 54(4): 708-13, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22978685
13.
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
Eur J Cancer
; 48(2): 179-86, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22119200
14.
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Clin Cancer Res
; 16(18): 4666-74, 2010 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20682708
15.
Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development.
Cancer Chemother Pharmacol
; 66(4): 785-95, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20062994
16.
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
J Thorac Oncol
; 5(7): 1060-7, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20526206
17.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Eur J Cancer
; 46(12): 2206-15, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20471824
18.
Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
Drug Metab Dispos
; 34(5): 775-82, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16455803
Resultados
1 -
18
de 18
1
Próxima >
>>